Current Report Filing (8-k)
24 May 2019 - 7:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 21, 2019
Precision
Therapeutics Inc.
(Exact name of Registrant as Specified
in its Charter)
Delaware
|
001-36790
|
83-4360734
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
2915 Commers Drive, Suite 900
Eagan, Minnesota
|
55121
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(651) 389-4800
Former Name or Former Address, if Changed
Since Last Report: Not Applicable
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
AIPT
|
Nasdaq Capital Market
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
Effective as of May 21, 2019, Precision
Therapeutics Inc. (the “Company”) and Carl Schwartz agreed to amend and restate in its entirety that certain Second
Amended and Restated Common Stock Purchase Warrant (the “Existing Warrant”) pursuant to a Third Amended and Restated
Common Stock Purchase Warrant (the “Warrant”). The Existing Warrant was issued in connection with Dr. Schwartz’s
additional $300,000.00 investment in the Company, as evidenced by that certain Second Amended and Restated Promissory Note in the
aggregate principal amount of $1,620,000.00 dated February 6, 2019 (the “Note”). The shares of the Company’s
common stock issuable in connection with an exercise of the Warrant are referred to herein as the “Warrant Shares”.
The Warrant has an exercise price of $0.836
per share for the initial 221,292 shares that related to Dr. Schwartz’s November 2018 investment (the “First Tranche”),
an exercise price of $0.704 per share for the additional 742,188 shares that related to Dr. Schwartz’s January 2019 investment
(the “Second Tranche”), an exercise price of $1.188 per share for the additional 138,889 shares that related to Dr.
Schwartz’s February 2019 investment (the “Third Tranche”) and an exercise price of $0.704 per share for each
installment of Additional Warrant Shares (as defined below) that will be added to the Warrant Shares. The exercise price in each
case is equal to 110% of the closing sale price of the common stock on the date of the applicable investment. Each tranche of the
Warrant is exercisable beginning on the sixth month anniversary of the date of the related investment through the fifth year anniversary
of the date of the related investment.
On February 1, 2019 and the first day of
each calendar month thereafter while the Note and the Warrant remain outstanding, a number of additional shares will be added to
the Warrant Shares (“Additional Warrant Shares”) equal to (1) one-half percent (1/2%) of the outstanding principal
balance of the Note on such date, divided by (2) $0.704, with the number of Additional Warrant Shares to be rounded to the nearest
number of whole shares. The principal change effected by the Third Amended and Restated Common Stock Purchase Warrant is to clarify
the formula for the calculation of the Additional Warrant Shares. The current principal balance of the Note is $1,620,000, and
therefore, under the amended formula, Dr. Schwartz is currently receiving rights under the Warrant to purchase Additional Warrant
Shares on the first day of each month equal to 11,506 shares of common stock at $0.704 per share.
The foregoing description of the Warrant
is qualified in its entirety by reference thereto, which is filed as Exhibit 4.1 to this Current Report, and is incorporated herein
by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(a) Not
applicable.
(b) Not
applicable.
(c) Not
applicable.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
PRECISION THERAPEUTICS inc.
|
|
|
|
By:
|
/s/ Bob Myers
|
|
|
Name: Bob Myers
Title: Chief Financial Officer
|
Date: May 23, 2019
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2024 to May 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Precision Therapeutics Inc. (NASDAQ): 0 recent articles
More Precision Therapeutics Inc. News Articles